Page last updated: 2024-09-04

dx 8951 and topotecan

dx 8951 has been researched along with topotecan in 10 studies

Compound Research Comparison

Studies
(dx 8951)
Trials
(dx 8951)
Recent Studies (post-2010)
(dx 8951)
Studies
(topotecan)
Trials
(topotecan)
Recent Studies (post-2010) (topotecan)
7318152,392626792

Protein Interaction Comparison

ProteinTaxonomydx 8951 (IC50)topotecan (IC50)
Cytochrome P450 3A4Homo sapiens (human)1.5211
DNA topoisomerase 1Homo sapiens (human)0.8525
DNA topoisomerase 2-alphaHomo sapiens (human)0.605
DNA topoisomerase 2-betaHomo sapiens (human)0.605
Hypoxia-inducible factor 1-alphaHomo sapiens (human)0.06
Multidrug and toxin extrusion protein 2Homo sapiens (human)8.6
Multidrug and toxin extrusion protein 1Homo sapiens (human)1.3
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.17

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (30.00)18.2507
2000's7 (70.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beijnen, JH; de Jong, LA; Hausheer, FH; Maliepaard, M; Pluim, D; Schellens, JH; Tohgo, A; van Gastelen, MA; van Waardenburg, RC1
Lombardo, F; Obach, RS; Waters, NJ1
Ishii, M; Joto, N; Kuga, H; Minami, M; Mitsui, I; Tohgo, A1
Kono, A; Kumazawa, E; Shimazoe, T; Takiguchi, S; Tohgo, A1
Clark, GM; De Jager, RL; Izbicka, E; Lawrence, RA; Rowinsky, EK; Tohgo, A; Von Hoff, DD; Weitman, SD1
Bevers, M; Kavanagh, JJ; Kudelka, AP; Levenback, C; Loyer, E; Verschraegen, CF; Vincent, M; Wolf, J1
Bailly, C; Lansiaux, A1
Bastien, L; De Jager, R; Duggal, A; Hu, W; Kavanagh, JJ; Kudelka, AP; Loyer, E; Verschraegen, CF; Vincent, M1
Al Harbi, T; Al-Faris, N; Doyle, J; Gassas, A; Goia, C; Pappo, A1
Herzog, TJ; Wethington, SL; Wright, JD1

Reviews

1 review(s) available for dx 8951 and topotecan

ArticleYear
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan

2008

Trials

2 trial(s) available for dx 8951 and topotecan

ArticleYear
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.
    Annals of the New York Academy of Sciences, 2000, Volume: 922

    Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Topotecan

2000
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan

2004

Other Studies

7 other study(ies) available for dx 8951 and topotecan

ArticleYear
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:4

    Topics: Acridines; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Survival; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Neoplasm Proteins; Tetrahydroisoquinolines; Tumor Cells, Cultured

2001
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    International journal of cancer, 1997, Aug-07, Volume: 72, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Water

1997
Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Japanese journal of cancer research : Gann, 1997, Volume: 88, Issue:8

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA Fragmentation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Splenic Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured

1997
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.
    Anti-cancer drugs, 1999, Volume: 10, Issue:7

    Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplastic Stem Cells; Topotecan; Tumor Cells, Cultured

1999
[A symphony for the camptothecins].
    Bulletin du cancer, 2003, Volume: 90, Issue:3

    Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan

2003
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
    Pediatric blood & cancer, 2007, Volume: 49, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infection Control; Kaplan-Meier Estimate; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Postoperative Care; Retrospective Studies; Risk; Salvage Therapy; Sarcoma, Ewing; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vincristine

2007